Rebamipide - Addpharma
Alternative Names: AD-203Latest Information Update: 11 Dec 2025
At a glance
- Originator Addpharma
- Class Amides; Amino acids; Anti-inflammatories; Antiulcers; Chlorobenzenes; Cytoprotectives; Eye disorder therapies; Propionic acids; Quinolones; Small molecules
- Mechanism of Action Oxygen radical formation antagonists; Oxygen radical scavengers; Prostaglandin agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Gastritis
Most Recent Events
- 11 Dec 2025 Rebamipide is still registered for Gastritis in South Korea (Addpharma pipeline, December 2025)
- 17 Sep 2025 Chemical structure information added.
- 31 Dec 2020 Registered for Gastritis (In the elderly, In adults) in South Korea (unspecified route) (Addpharma website, January 2023)